secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310469
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH
-------------------------------------------------------------------

- In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
- In 2L setting (n=18 evaluable, 94% primary refractory): 83% ORR, 61% CR; median duration of CR not reached.
- Safety (n=69): no Grade ≥3 CRS; one Grade ≥3 ICANS case (4% with dex prophylaxis); no treatment-related deaths.
- Ronde-cel showed up to 3-fold higher expansion vs approved CD19 CAR-T products and higher memory-cell phenotype.
- Data cutoff Sep 5, 2025; ronde-cel is dual-targeting CD19/CD20 CAR-T with CD62L enrichment manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525310469/0001193125-25-310469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525310469/d35459d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer